For: | Cheah E, Huang JG. Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. World J Gastroenterol 2023; 29(10): 1539-1550 [PMID: 36970587 DOI: 10.3748/wjg.v29.i10.1539] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i10/1539.htm |
Number | Citing Articles |
1 |
Luyao Liu, Fan Zhao, Dandan Han, Xin Lü, Gang Wu, Yanglei Yi. Liquiritigenin ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function, reducing endoplasmic reticulum stress and modulating gut microbiota. Journal of Functional Foods 2024; 122: 106541 doi: 10.1016/j.jff.2024.106541
|
2 |
Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations. World Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411
|
3 |
Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments at the year-end of 2023. World Journal of Gastroenterology 2024; 30(1): 1-8 doi: 10.3748/wjg.v30.i1.1
Abstract(568) |
Core Tip(542) |
Full Article(HTML)(3305)
|
Full Article with Cover (PDF)-1825K(196)
|
Full Article (Word)-130K(37)
|
Audio-14227K(20)
|
Peer-Review Report-222K(67)
|
Answering Reviewers-194K(55)
|
Full Article (PDF)-407K(177)
|
Full Article (XML)-119K(69)
|
Times Cited (0)
|
Total Visits (9994)
|
Open
|
4 |
Danny Con, Peter De Cruz. Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study. Intestinal Research 2024; 22(4): 439 doi: 10.5217/ir.2023.00175
|
5 |
Fang-Yuan Zheng, Kai-Si Yang, Wen-Cheng Min, Xin-Zhu Li, Yu Xing, Shuai Wang, Ying-Shi Zhang, Qing-Chun Zhao. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis. World Journal of Gastrointestinal Surgery 2024; 16(2): 571-584 doi: 10.4240/wjgs.v16.i2.571
Abstract(279) |
Core Tip(331) |
Full Article(HTML)(994)
|
Full Article with Cover (PDF)-2615K(67)
|
Full Article (Word)-1431K(6)
|
Audio-2064K(1)
|
Peer-Review Report-254K(42)
|
Answering Reviewers-134K(38)
|
Supplementary Material-222K(38)
|
Full Article (PDF)-2359K(79)
|
Full Article (XML)-155K(40)
|
Times Cited (0)
|
Total Visits (3672)
|
Open
|
6 |
Daniel Schweckendiek, Gerhard Rogler. Antibodies Targeting the Tumor Necrosis Factor-Like Ligand 1A in Inflammatory Bowel Disease: A New Kid on the (Biologics) Block?. Digestion 2024; 105(6): 411 doi: 10.1159/000540421
|